Compare Cassava Sciences Inc (FLNA) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while State Street SPDR S&P Homebuilders ETF trades at $108.71. The key difference: State Street SPDR S&P Homebuilders ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | XHB | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $121.36 |
52-Week Low | $0.87 | $94.86 |
Enterprise Value | -$34.93M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
XHB trades at $108.22, down slightly by 0.02% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights mixed housing data, including a 1.6% rise in new home sales in June 2026 (Census Bureau, 2026-07-24) but a 2.4% drop in existing home sales (CNBC, 2026-07-09). The ETF benefits from a new housing affordability law (Zacks Investment Research, 2026-07-13), though financial ratios are unavailable.
Outlook is cautiously optimistic due to policy support and technical strength, but risks include high mortgage rates and volatile home sales. Investors should weigh bullish momentum against macroeconomic headwinds in the housing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
